Sangamo Therapeutics Inc (NASDAQ:SGMO)’s share price rose 3.6% during mid-day trading on Thursday . The company traded as high as $22.53 and last traded at $21.30. Approximately 1,206,079 shares changed hands during trading, a decline of 23% from the average daily volume of 1,561,221 shares. The stock had previously closed at $22.10.

SGMO has been the subject of a number of analyst reports. Piper Jaffray Companies set a $25.00 target price on Sangamo Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. BidaskClub raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Zacks Investment Research raised Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Wednesday, November 15th. Jefferies Group reissued a “buy” rating and set a $18.00 target price on shares of Sangamo Therapeutics in a research note on Friday, October 13th. Finally, Wedbush reissued a “hold” rating and set a $6.00 target price on shares of Sangamo Therapeutics in a research note on Wednesday, November 15th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $18.83.

The company has a market capitalization of $1,800.00, a P/E ratio of -30.07 and a beta of 2.87. The company has a quick ratio of 5.64, a current ratio of 5.64 and a debt-to-equity ratio of 0.02.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The firm had revenue of $11.81 million during the quarter, compared to the consensus estimate of $10.37 million. During the same period last year, the business posted ($0.27) EPS. Sangamo Therapeutics’s quarterly revenue was up 333.0% on a year-over-year basis. equities research analysts predict that Sangamo Therapeutics Inc will post -0.73 EPS for the current fiscal year.

In related news, VP Curt A. Herberts III sold 16,630 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $16.13, for a total value of $268,241.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Saira Ramasastry sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $14.67, for a total value of $73,350.00. Following the completion of the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at $73,350. The disclosure for this sale can be found here. Insiders sold a total of 89,953 shares of company stock valued at $1,618,193 over the last ninety days. 5.50% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SGMO. Quantbot Technologies LP acquired a new stake in Sangamo Therapeutics during the 3rd quarter valued at $118,000. Amalgamated Bank acquired a new stake in Sangamo Therapeutics during the 3rd quarter valued at $158,000. Chicago Equity Partners LLC acquired a new stake in Sangamo Therapeutics during the 4th quarter valued at $192,000. Great West Life Assurance Co. Can grew its holdings in Sangamo Therapeutics by 150.3% during the 3rd quarter. Great West Life Assurance Co. Can now owns 12,767 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 7,667 shares during the last quarter. Finally, Principal Financial Group Inc. grew its holdings in Sangamo Therapeutics by 6.8% during the 2nd quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 832 shares during the last quarter. 64.06% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Sangamo Therapeutics (SGMO) Trading Up -3.6%” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2018/02/08/sangamo-therapeutics-sgmo-trading-up-3-6.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.